Madrigal Pharmaceuticals found using ticker (MDGL) have now 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 230 and 123 with a mean TP of 170. With the stocks previous close at 118.34 this indicates there is a potential upside of 43.7%. The 50 day MA is 120.66 and the 200 day MA is 114.83. The company has a market capitalisation of $1,824m. Company Website: http://www.madrigalpharma.com
Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) Ã-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-Ã-selective small molecule that is in preclinical trials for the treatment of NASH and hyperlipidemia. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.